Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijantimicag.2020.105984 http://scihub22266oqcxt.onion/10.1016/j.ijantimicag.2020.105984 32305589!7162749!32305589     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32305589.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Int+J+Antimicrob+Agents 2020 ; 56 (2): 105984 Nephropedia Template TP {{tp|p=32305589|t=2020. Combating devastating COVID-19 by drug repurposing |pdf=|usr=}}{{32305589}} gab.com Text Combating devastating COVID-19 by drug repurposing JO: Int J Antimicrob Agents http://www.kidney.de/pget.php?&tw=1&pmid=32305589 #FOAvip Despite advances in drug discovery, viral infections remain a major challenge for scientists across the globe. The recent pandemic of COVID-19 (coronavirus disease 2019), caused by a viral infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has created a disastrous situation all over the world. As no drugs are available to treat this life-threatening disease and the mortality rate due to COVID-19 is high, there is an utmost need to attempt to treat the infection using drug repurposing. Some countries are against the use of these drugs because of adverse effects associated with drug repurposing and lack of statistically significant clinical data, but they have been found to be effective in some countries to treat COVID-19 patients (off-label/investigational). This article emphasises possible drug candidates in the treatment of COVID-19. Most of these drugs were found to be effective in in vitro studies. There is a need to re-assess in vitro data and to carry out randomised clinical trials. Further investigations of these drugs are recommended on a priority basis. Twit Text FOAVip Combating devastating COVID-19 by drug repurposing ????Int J Antimicrob Agents http://www.kidney.de/pget.php?&tw=1&pmid=32305589 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32305589 #FOAvip English Wikipedia <ref>{{Cite pmid|32305589}}</ref> Combating devastating COVID-19 by drug repurposing #MMPMID32305589 Pawar AY Int J Antimicrob Agents 2020[Aug]; 56 (2): 105984 PMID32305589show ga Despite advances in drug discovery, viral infections remain a major challenge for scientists across the globe. The recent pandemic of COVID-19 (coronavirus disease 2019), caused by a viral infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has created a disastrous situation all over the world. As no drugs are available to treat this life-threatening disease and the mortality rate due to COVID-19 is high, there is an utmost need to attempt to treat the infection using drug repurposing. Some countries are against the use of these drugs because of adverse effects associated with drug repurposing and lack of statistically significant clinical data, but they have been found to be effective in some countries to treat COVID-19 patients (off-label/investigational). This article emphasises possible drug candidates in the treatment of COVID-19. Most of these drugs were found to be effective in in vitro studies. There is a need to re-assess in vitro data and to carry out randomised clinical trials. Further investigations of these drugs are recommended on a priority basis. |*Drug Repositioning[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/*isolation & purification[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH]Combating devastating COVID-19 by drug repurposing (epmc).pdf DeepDyve Pubget Overpricing